Patents by Inventor Richard A. WALGREN

Richard A. WALGREN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY WITH MERESTINIB AND ANTI-PD-L1 OR ANTI-PD-1 INHIBITORS FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20190269666
    Abstract: The present invention relates to a combination therapy with N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (merestinib, LY2801653), or a pharmaceutically acceptable salt thereof, and antibodies that bind human co-inhibitory immune checkpoints such as Programmed Death 1 Ligand 1 (PD-L1) or Programmed Death 1 (PD-1) for the treatment of various cancers.
    Type: Application
    Filed: July 21, 2017
    Publication date: September 5, 2019
    Inventors: David Arlen SCHAER, Richard A. WALGREN, Sau-Chi Betty YAN
  • COMBINATION THERAPY FOR CANCER
    Publication number: 20180207268
    Abstract: The present invention relates to a combination of an anti-human VEGFR2 antibody, preferably ramucirumab, and N-(3-fluoro-4-(1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yloxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2- dihydropyridine-3-carboxamide, and to methods of using the combination to treat certain disorders, such as gastric cancer.
    Type: Application
    Filed: August 10, 2016
    Publication date: July 26, 2018
    Applicant: ImClone LLC
    Inventors: Sudhakar R. CHINTHARLAPALLI, Anthony S. FISCHL, Victoria Lynn PEEK, Richard A. WALGREN, Sau Chi Betty YAN